Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Особенности антиишемического эффекта триметазидина MB в комбинации с метопрололом у больных со стенокардией
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: стенокардия напряжения, антиишемический эффект, углеводный обмен, триметазидин МВ, метопролол.
________________________________________________
We studied the influence of trimetazidine MR on exercise tolerance and carbohydrate metabolism in 28 patients with stable effort angina, treated with metoprolol. The addition of trimetazidine MR to ongoing therapy with metoprolol substantially enhanced the antianginal and anti-ischemic efficacy of treatment. The most significant improvement was observed when the monotherapy with metoprolol wasn’t effective. In this subgroup of patients the threshold exercise duration increased by 77,1±18,1 s (p<0,05), the angina frequency decreased by 5,0±2,3 attacks per week (p<0,001) in comparison with metoprolol. Trimetazidine MR didn’t change the fasting blood glucose and insulin level and the index of fasting insulin resistance HOMA2-IR.
Key words: stable effort angina, anti-ischemic effect, carbohydrate metabolism, trimetazidine MR, metoprolol.
2. Daly CA, Clemens F, Sendon JLL, Tavazzi L et al. The initial management of stable angina in Europe from Euro Heart Survey. A description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heat J 2005; 26: 1011–22.
3. Guidelines on the management of stable angina pectoris: executive summary. Task Force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.
4. Диагностика и лечение стабильной стенокардии. Российские рекомендации, 2-й пересмотр. Кардиоваск. терапия и профилактика. 2008; 7 (6): 3–40.
5. Метелица В.И., Бочкарева Е.В., Кокурина Е.В. и др. Индивидуальный выбор антиангинальных препаратов с помощью парных ВЭМ-тестов у больных стенокардией. Терапевт. арх. 1992; 9: 35–9.
6. Бутина Е.К., Кокурина Е.В., Дмитриева Н.А. и др. Сниженная чувствительность к антиишемическому эффекту пропранолола и возможность ее коррекции у больных стабильной стенокардией. Терапевт. арх. 2002; 34–9.
7. Sharma V, Dhillon P, Wambolt R et al. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am J Physiol Heart Circ Physiol 2008; 294: H1609–H1620.
8. Moro C, Polak J, Klimcakova E et al. Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise. Am J Physiol Endicrinol Metab 2006; 290 (5): E864–9.
9. Moro C, Pillard F, Glisezinski I et al. Exercise-induced lipid mobilization in subcutaneuos adipose tissue is mainly related to natriuretic peptides in overweight men. Am J Physiol Endocrinol Metab 2008; 295 (2): E505–13.
10. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. Q J Med 2006; 99: 431–6.
11. Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artery Dis 2004; 15 (1): 17–2.
12. Ribeiro LW, Ribeiro JP, Stein R et al. Trimetazidine added to combined hemodynamic anitianginal therapy in patients with type 2 diabetes: a randomized crossover trial. Am Heart J 2007; 154 (1): 78.e1–7.
13. Fragasso G, Piatti PM, Monti L et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyoparthy. Am Heart J 2003; 146 (5): Е18.
14. Cai JS, Peng ZJ. Effect of trimetazidine on insulin resistance in patients with coronary heart disease. Nan fang Yi Ke Da Xue Xue Bao 2006; 26 (2): 222–6.
15. Wallace NM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–95.
16. Geloneze B, Vasques ACJ, Stabe CFC et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome – Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metab 2009; 53 (2): 281–7.
17. Vardeny O, Zebrack J, Gilbert EM. Effects of beta-blocker titration on glucose homeostasis in heart failure. J Pharm Technol 2009; 25 (2): 71–8.
18. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580–8.
ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава РФ
________________________________________________
P.Yu.Bardybakhin, E.V.Bochkareva, I.V.Kim
State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation